Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study

Abstract Background Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs. Methods We selected patients...

Full description

Saved in:
Bibliographic Details
Published in:CMAJ open Vol. 1; no. 4; pp. E151 - E158
Main Authors: de Oliveira, Claire, PhD, Bremner, Karen E., BSc, Pataky, Reka, MSc, Gunraj, Nadia, MPH, Haq, Mahbubul, MSc, Chan, Kelvin, MD MSc, Cheung, Winson Y., MD MPH, Hoch, Jeffrey S., PhD, Peacock, Stuart, DPhil, Krahn, Murray D., MD MSc
Format: Journal Article
Language:English
Published: Canada Canadian Medical Association 09-12-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs. Methods We selected patients aged 19–44 years who had received a diagnosis of melanoma, breast cancer (female only), testicular cancer or thyroid cancer, in addition to patients aged 45 years and older who had received a diagnosis of breast (female only), prostate, lung or colorectal cancer, between 1997 and 2007. Patients were identified from the Ontario Cancer Registry. Using linked administrative databases, we determined use and costs of chemotherapy, radiotherapy, cancer-related surgery, other admissions to hospital and home care. We adjusted all costs to 2009 Canadian dollars. Results We identified 20 821 patients aged 19–44 years and 178 797 patients aged 45 years and older. The greatest increases in costs during the study period were for melanoma, breast cancer, colorectal cancer, lung cancer and prostate cancer ( p < 0.05). For prostate and lung cancers, mean costs increased 50% (from $11 490 and $22 037 to $15 170 and $34 473, respectively). Mean costs doubled for breast (from $15 460 and $12 909 to $35 977 and $29 362 for younger and older patients, respectively) and colorectal cancers (from $24 769 to $43 964), and nearly tripled for melanoma (from $3581 to $8934). Costs related to hospital admissions accounted for the largest portion of total costs. The use of chemotherapy, radiotherapy and home care generally increased for all cancers. Interpretation The significant increase in mean costs of initial cancer treatment among the patients included in this study was primarily due to more patients receiving adjuvant therapy and home care, and to the increasing expenditures for these services and cancer-related surgeries. Understanding trends in health care use and costs can help policy-makers to take the necessary measures to achieve a more accountable, high-performing health care system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing interests:None declared.[[Dr. Hoch’s copyright and ICMJE disclosure forms still to come.]]
Disclaimer:This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.
Contributors:Claire de Oliveira contributed to the conceptualization and design of the study, analyzed and interpreted the data and drafted the manuscript. Karen Bremner, Reka Pataky, Kelvin Chan, Winson Cheung, Jeffrey Hoch, Stuart Peacock and Murray Krahn contributed to the conceptualization and design of the study, analyzed and interpreted the data, and revised the manuscript for important intellectual content. Nadia Gunraj selected the patient cohort and linked it with administrative health care data housed at the Institute for Clinical and Evaluative Sciences, Toronto, Ont. Nadia Gunraj and Mahbubul Haq analyzed and interpreted the data and revised the manuscript for important intellectual content. All of the authors approved the final version of the manuscript submitted for publication.
Funding:This project was funded by a research grant from the Canadian Cancer Society Research Institute (grant no. 020200). Murray Krahn is supported by the F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto, Toronto, Ont.
ISSN:2291-0026
2291-0026
DOI:10.9778/cmajo.20130041